ARTICLE | Discovery & Translation
BioCentury’s roundup of translational innovations
By Danielle Golovin, Biopharma Analyst
November 10, 2023 11:59 PM UTC
Shinobi Therapeutics and collaborators at the University of California San Francisco described in Cell Stem Cell a method to prevent innate immune cell killing of allogeneic cell therapies. The authors, including Sana Biotechnology Inc. (NASDAQ:SANA) scientific founder Sonja Schrepfer, showed immune checkpoint engagers that activate inhibitory innate immune cell receptors TIM3 and SIRPA protected engineered human leukocyte antigen (HLA)-depleted induced pluripotent stem cell-derived endothelial cells from killing by NK cells and macrophages. Combining the engagers with a truncated CD64, which evades cytotoxic IgG, allowed for complete immune evasion.
UCSF filed patent applications that cover the work…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/650615/shinobi-s-immune-protected-cell-therapies-plus-emugen-az-and-more